



#28
E-116
10-9-02
P.2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Schreiber et al.

Serial No.: 08/922,240

Filed: August 27, 1997

For: Gene Therapy by Cell Specific Targeting

Atty. Docket No: APBI-P01-007

Art Unit: 1633

Examiner: Sorbello, E.

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Assistant Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

September 27, 2002

Date of Signature
and of Mail Deposit

Brent LaBarge

Box AF
Assistant Commissioner for Patents
Washington, DC 20231

RECEIVED

OCT 09 2002

RESPONSE AND AMENDMENT

TECH CENTER 1600/2900

Dear Sir:

Applicants submit this Response and Amendment in response to the final Office Action dated March 27, 2002. A Notice of Appeal and Petition for a three-month extension of time and appropriate fees are filed concurrently herewith.

For the convenience of the Examiner, all claims being examined, whether or not amended, are presented below. A marked-up version is provided after the clean version.

Please amend the claims as follows:

Please cancel claims 2, 3, 17, 27, 30, 31, and 40-43 without prejudice.

1. (Amended) A method for preferentially inhibiting T cells which include a recombinant gene encoding a mutated macrolide binding protein (MBP) selected from an FK506-binding protein (FKBP), cyclophilin, calcineurin, and FKBP:rapamycin associated protein (FRAP), which method comprises contacting the cell with a macrolide which